CombiGene AB (publ): Nominating committee

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2020 The AGM 2020 resolved that a nominating committee should be appointed...

read more

Horizon 2020 continues to invest in CombiGene´s epilepsy project

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation...

read more

Interim Report January – September 2020

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Interim Report January – September 2020 for CombiGene AB (publ)för CombiGene AB (publ) About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the...

read more

Updated analysis of CombiGene

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Analysguiden has today updated its analysis of CombiGene. You can find the result here: https://www.aktiespararna.se/analysguiden/article/796368 2021 » News » Regulatory news » Financial reports...

read more

Interim Report January – June 2020

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Interim Report January – June 2020 for CombiGene AB (publ) >> 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook